| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.IJPHARM.2013.05.061 |
| P698 | PubMed publication ID | 23751341 |
| P2093 | author name string | R O Williams | |
| Chris Brough | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanotechnology | Q11468 |
| drug delivery | Q1392806 | ||
| P304 | page(s) | 157-166 | |
| P577 | publication date | 2013-06-07 | |
| P1433 | published in | International Journal of Pharmaceutics | Q6051539 |
| P1476 | title | Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery | |
| P478 | volume | 453 |
| Q89910020 | A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein |
| Q38985268 | A recent trend of drug-nanoparticles in suspension for the application in drug delivery. |
| Q92279311 | Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds |
| Q101051216 | Amorphous solid dispersions of enzalutamide and novel polysaccharide derivatives: investigation of relationships between polymer structure and performance |
| Q30375813 | An Intensified Vibratory Milling Process for Enhancing the Breakage Kinetics during the Preparation of Drug Nanosuspensions. |
| Q64984261 | Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation⁻Processing Aspects and Challenges. |
| Q38954732 | Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir. |
| Q38573948 | Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A Review |
| Q49092618 | Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying. |
| Q51671101 | Crystallization of undercooled liquid fenofibrate. |
| Q42720527 | Disintegration mediated controlled release supersaturating solid dispersion formulation of an insoluble drug: design, development, optimization, and in vitro evaluation |
| Q92650959 | Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males |
| Q93345097 | Effect of Particle Size and Polymer Loading on Dissolution Behavior of Amorphous Griseofulvin Powder |
| Q64942869 | Electrosprayed Nanosystems of Carbamazepine - PVP K30 for Enhancing Its Pharmacologic Effects. |
| Q58617383 | Electrospun Produced 3D Matrices for Covering of Vascular Stents: Paclitaxel Release Depending on Fiber Structure and Composition of the External Environment |
| Q47852767 | Enhanced Dissolution of a Porous Carrier-Containing Ternary Amorphous Solid Dispersion System Prepared by a Hot Melt Method |
| Q37180037 | Eupafolin nanoparticles protect HaCaT keratinocytes from particulate matter-induced inflammation and oxidative stress |
| Q92637101 | Fluoroquinolone Amorphous Polymeric Salts and Dispersions for Veterinary Uses |
| Q35981768 | Formation of Organic Molecular Nanocrystals under Soft Confinement |
| Q42012855 | Formulation of gammaoryzanol-loaded nanoparticles for potential application in fortifying food products |
| Q26822873 | Fundamental aspects of solid dispersion technology for poorly soluble drugs |
| Q35586493 | Hydroxypropyl-β-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs |
| Q90667750 | Impact of Hot-Melt Extrusion Processing Conditions on Physicochemical Properties of Amorphous Solid Dispersions Containing Thermally Labile Acrylic Copolymer |
| Q89618605 | Improved solubility, dissolution rate, and oral bioavailability of main biflavonoids from Selaginella doederleinii extract by amorphous solid dispersion |
| Q89910071 | In vitro/vivo assessment of praziquantel nanocrystals: Formulation, characterization, and pharmacokinetics in beagle dogs |
| Q50161058 | Melt extrusion with poorly soluble drugs - An integrated review |
| Q47810974 | Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance |
| Q58726467 | Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability |
| Q61455125 | Nanocrystals: A perspective on translational research and clinical studies |
| Q38687039 | Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles. |
| Q26746912 | Nanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective. |
| Q37601242 | Nanotherapeutics in the EU: an overview on current state and future directions |
| Q47898757 | Polymer/Amorphous Salt Solid Dispersions of Ciprofloxacin |
| Q38737245 | Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs |
| Q38696042 | Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders |
| Q89854076 | Synthesis of a Porous C3N-Derived Framework with High Yield by Gallic Acid Cross-Linking Using Salt Melts |
| Q36360522 | The Stabilization of Amorphous Zopiclone in an Amorphous Solid Dispersion |
| Q38411345 | Theory and practice of supersaturatable formulations for poorly soluble drugs. |
| Q38619443 | Thermal Processing of PVP- and HPMC-Based Amorphous Solid Dispersions. |
| Q57369359 | Unimolecular branched block copolymer nanoparticles in methanol for the preparation of poorly water-soluble drug nanoparticles |
| Q38619498 | Use of Polyvinyl Alcohol as a Solubility Enhancing Polymer for Poorly Water-Soluble Drug Delivery (Part 2) |
| Q38619585 | Use of Polyvinyl Alcohol as a Solubility-Enhancing Polymer for Poorly Water Soluble Drug Delivery (Part 1). |
Search more.